William Petty to Disease-Free Survival
This is a "connection" page, showing publications William Petty has written about Disease-Free Survival.
Connection Strength
0.198
-
Petty WJ, Laudadio J, Brautnick L, Lovato J, Dotson T, Streer NP, Weaver KE, Miller AA. Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer. Int J Oncol. 2013 Dec; 43(6):2057-63.
Score: 0.107
-
Shenker RF, McTyre ER, Ruiz J, Weaver KE, Cramer C, Alphonse-Sullivan NK, Farris M, Petty WJ, Bonomi MR, Watabe K, Laxton AW, Tatter SB, Warren GW, Chan MD. The Effects of smoking status and smoking history on patients with brain metastases from lung cancer. Cancer Med. 2017 May; 6(5):944-952.
Score: 0.034
-
Kilburn JM, Soike MH, Lucas JT, Ayala-Peacock D, Blackstock W, Isom S, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ. Image guided radiation therapy may result in improved local control in locally advanced lung cancer patients. Pract Radiat Oncol. 2016 May-Jun; 6(3):e73-e80.
Score: 0.031
-
Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol. 2012 Nov 10; 30(32):3953-9.
Score: 0.025